Sangamo Therapeutics (SGMOQ) Net Equity Issued and Repurchased (2010 - 2025)

Sangamo Therapeutics has reported Net Equity Issued and Repurchased for 16 years, with the latest figure at -$106000.0 in Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$106000.0 in Q3 2025; TTM through Dec 2025 was $21.5 million, a 1.72% decrease from a year earlier, with the FY2025 full-year figure at $21.5 million, down 1.72% from the prior year.
• Net Equity Issued and Repurchased was -$106000.0 for Q3 2025 at Sangamo Therapeutics, down from $11.2 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $43.9 million in Q3 2022, with the low at -$13.6 million in Q2 2021.
• Average Net Equity Issued and Repurchased over 5 years is $12.2 million, with a median of $10.8 million recorded in 2025.
• The sharpest annual moves came in 2021 and 2024: Net Equity Issued and Repurchased sank 1245.49% in 2021, then jumped 265.77% in 2024.
• Over 5 years, Net Equity Issued and Repurchased stood at $25.0 million in 2021, then dropped by 24.05% to $19.0 million in 2022, then plunged by 99.99% to $1000.0 in 2023, then sank by 6600.0% to -$65000.0 in 2024, then slumped by 63.08% to -$106000.0 in 2025.
• The last three Net Equity Issued and Repurchased figures came in at -$106000.0 (Q3 2025), $11.2 million (Q2 2025), and $10.4 million (Q1 2025), per Business Quant data.